Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGF versus GFF crossover imaging study in moderate to severe COPD
NL-OMON48928Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Specific image-based airway volumes and resistance. Started Feb 2019; status: active, not recruiting.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON48928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48928.